Cognitive enhancement can be defined as the use of drugs and/or other means with the aim to improve the cognitive functions of healthy subjects in particular memory, attention, creativity and intelligence in the absence of any medical indication. Currently, it represents one of the most debated topics in the neuroscience community. Human beings always wanted to use substances to improve their cognitive functions, from the use of hallucinogens in ancient civilizations in an attempt to allow them to better communicate with their gods, to the widespread use of caffeine under various forms (energy drinks, tablets, etc.), to the more recent development of drugs such as stimulants and glutamate activators. In the last ten years, increasing attention has been given to the use of cognitive enhancers, but up to now there is still only a limited amount of information concerning the use, effect and functioning of cognitive enhancement in daily life on healthy subjects. The first aim of this paper was to review current trends in the misuse of smart drugs (also known as Nootropics) presently available on the market focusing in detail on methylphenidate, trying to evaluate the potential risk in healthy individuals, especially teenagers and young adults. Moreover, the authors have explored the issue of cognitive enhancement compared to the use of Anabolic Androgenic Steroids (AAS) in sports. Finally, a brief overview of the ethical considerations surrounding human enhancement has been examined.

Smart drugs and synthetic androgens for cognitive and physical enhancement: revolving doors of cosmetic neurology / Frati, Paola; DEL RIO, Alessandro; Marinelli, Enrico; MONTANARI VERGALLO, Gianluca; Zaami, Simona; Francesco P., Busardò; Kyriakou, Chrystalla. - In: CURRENT NEUROPHARMACOLOGY. - ISSN 1570-159X. - ELETTRONICO. - 1:13(2015), pp. 5-11. [10.2174/1570159X13666141210221750]

Smart drugs and synthetic androgens for cognitive and physical enhancement: revolving doors of cosmetic neurology

FRATI, PAOLA;DEL RIO, Alessandro;MARINELLI, Enrico;MONTANARI VERGALLO, GIANLUCA;ZAAMI, Simona;KYRIAKOU, CHRYSTALLA
2015

Abstract

Cognitive enhancement can be defined as the use of drugs and/or other means with the aim to improve the cognitive functions of healthy subjects in particular memory, attention, creativity and intelligence in the absence of any medical indication. Currently, it represents one of the most debated topics in the neuroscience community. Human beings always wanted to use substances to improve their cognitive functions, from the use of hallucinogens in ancient civilizations in an attempt to allow them to better communicate with their gods, to the widespread use of caffeine under various forms (energy drinks, tablets, etc.), to the more recent development of drugs such as stimulants and glutamate activators. In the last ten years, increasing attention has been given to the use of cognitive enhancers, but up to now there is still only a limited amount of information concerning the use, effect and functioning of cognitive enhancement in daily life on healthy subjects. The first aim of this paper was to review current trends in the misuse of smart drugs (also known as Nootropics) presently available on the market focusing in detail on methylphenidate, trying to evaluate the potential risk in healthy individuals, especially teenagers and young adults. Moreover, the authors have explored the issue of cognitive enhancement compared to the use of Anabolic Androgenic Steroids (AAS) in sports. Finally, a brief overview of the ethical considerations surrounding human enhancement has been examined.
2015
anabolic androgenic steroids (AAS); human enhancement; cosmetic neurology; methylphenidate; smart drugs; anabolic agents; designer drugs; humans; neuropharmacology; nootropic agents; street drugs; substance-related disorders; testosterone congeners; cosmetics
01 Pubblicazione su rivista::01a Articolo in rivista
Smart drugs and synthetic androgens for cognitive and physical enhancement: revolving doors of cosmetic neurology / Frati, Paola; DEL RIO, Alessandro; Marinelli, Enrico; MONTANARI VERGALLO, Gianluca; Zaami, Simona; Francesco P., Busardò; Kyriakou, Chrystalla. - In: CURRENT NEUROPHARMACOLOGY. - ISSN 1570-159X. - ELETTRONICO. - 1:13(2015), pp. 5-11. [10.2174/1570159X13666141210221750]
File allegati a questo prodotto
Non ci sono file associati a questo prodotto.

I documenti in IRIS sono protetti da copyright e tutti i diritti sono riservati, salvo diversa indicazione.

Utilizza questo identificativo per citare o creare un link a questo documento: https://hdl.handle.net/11573/636987
 Attenzione

Attenzione! I dati visualizzati non sono stati sottoposti a validazione da parte dell'ateneo

Citazioni
  • ???jsp.display-item.citation.pmc??? 11
  • Scopus 54
  • ???jsp.display-item.citation.isi??? 73
social impact